Management of infusion-related reactions (IRRs) in patients receiving amivantamab

What is it about?

This study focuses on managing infusion-related reactions (IRRs) in patients treated with amivantamab, a bispecific antibody targeting EGFR and MET, for non-small cell lung cancer (NSCLC). Amivantamab has shown promising efficacy in treating NSCLC, particularly in patients with EGFR exon 20 insertion mutations. However, IRRs are a common side effect. The study analyzed patients from the CHRYSALIS trial, detailing the occurrence, management, and mitigation strategies of IRRs during amivantamab treatment. Strategies included a split first dose, reduced initial infusion rates, and premedication with steroids, antihistamines, and antipyretics. The majority of IRRs were mild to moderate, occurring mainly during the first infusion and managed effectively with these strategies, allowing most patients to continue treatment.

Featured Image

Photo by National Cancer Institute on Unsplash

Photo by National Cancer Institute on Unsplash

Why is it important?

Amivantamab offers a new therapeutic option for NSCLC patients with specific genetic mutations, where few treatments were available. Understanding and managing IRRs are crucial for ensuring patient safety and treatment efficacy. This study is significant as it provides insights into the frequency and severity of IRRs associated with amivantamab and outlines effective management strategies. These findings help clinicians anticipate and mitigate IRRs, ensuring that patients can receive this potentially life-extending treatment with minimal discomfort and risk. The study’s insights contribute to the broader knowledge of administering novel cancer therapies safely, enhancing patient care in oncology. Key Takeaways: 1. Amivantamab's Efficacy: Demonstrates significant antitumor activity in NSCLC, especially in EGFR exon 20 insertion mutations. 2. Common Side Effect: IRRs frequently occur with amivantamab but are mostly low-grade and manageable. 3. Effective Management Strategies: Include split dosing, reduced infusion rates, and premedication to mitigate IRRs. 4. Continued Treatment Feasibility: The majority of patients can continue amivantamab treatment after experiencing IRRs. 5. Need for Further Research: While IRR mechanisms are not fully understood, ongoing studies aim to improve patient experience and safety.